ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

HK$2.81As of Sun 8 Nov 2026, 12:00 UTC
HKEX:1541Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 3Y CAGR (53.82%)
Div yield —
ROE (40.11%)
Biotechnology
Beta (5Y) 0.29
PE TTM —
TSR TTM (69.41%)
Mkt cap HK$1.205B
ROIC (15.96%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.62
29.14%
386.31%
Hold 6|2|6|12|5
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.05
0.05
0.05
0.05
22.77%
37.50%
22.60%
6.28%
Revenue¥M
140.5
147.0
154.7
161.7
10.11%
11.99%
16.84%
21.73%
Peers (US$153.7M)
Cap (US$)
PE
170.4M
—
168.3M
—
140.4M
6.941x
Capital
TTM
5Y
10Y
Leveragex
0.124
1.260
1.094
EBIT/Intx
0.129
0.319
0.207
Own earn%
(162.51)
(184.04)
(167.04)
Sh yield%
29.84
32.27
33.34
Owners
Insiders/Inst%
7.23
35.09
Short interest%
4.67
SBC / revenue%
1.70
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
2–5
$1 testx
0.0
Incr. ROIC%
4